- The report contains detailed information about OncoGenex Pharmaceuticals, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for OncoGenex Pharmaceuticals, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The OncoGenex Pharmaceuticals, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes OncoGenex Pharmaceuticals, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of OncoGenex Pharmaceuticals, Inc. business.
About OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer.
The company has five product candidates in its pipeline: OGX-011, OGX-427, OGX-225, SN2310 and CSP-9222, with each product candidate having a distinct mechanism of action and representing an opportunity for cancer drug development.
Through clinical trials, the company is in the process of treating cancer patients with OGX-011 to reduce clusterin production. The company, in December 2009, announced that its wholly-owned subsidiary, OncoGenex Technologies Inc. (OncoGenex Technologies), entered into a collaboration and license agreement with Teva Pharmaceutical Industries Ltd., for the development and global commercialization of OGX-011 (and related compounds targeting clusterin.
OGX-427, an inhibitor of heat shock protein 27, is being evaluated in a phase 1 clinical trial to evaluate safety for OGX-427 administered alone, as well as in combination with docetaxel chemotherapy (docetaxel), in patients with various types of cancer.
SN2310, OGX-225 and CSP-9222
SN2310 was evaluated in a phase 1 clinical trial to evaluate safety in patients with advanced cancer who have received on average 3 to 5 prior chemotherapy treatments. The phase 1 clinical trial has been completed. The company is in the process of exploring options to out-license this product candidate.
OGX-225 is a second generation antisense drug which in preclinical experiments, inhibits production of both Insulin Growth Factor Binding Protein 2 (IGFBP-2) and Insulin Growth Factor Binding Protein-5 (IGFBP-5).
Product candidate CSP-9222, in pre-clinical development, is the main compound from a family of compounds, which have been in-licensed from Bayer Healthcare LLC (Bayer) that demonstrates activation of programmed cell death in pre-clinical models.
OGX-011: In November 2001, OncoGenex Technologies entered into an agreement with Isis Pharmaceuticals, Inc. (Isis) to jointly develop and commercialize OGX-011. This strategic relationship provided the company with access to Isis proprietary position in second-generation antisense chemistry for use in OGX-011, Isis expertise in developing antisense therapeutics.
OGX-427: In January 2005, OncoGenex Technologies entered into a collaboration and license agreement with Isis to jointly identify antisense compounds designed to inhibit the production of proteins encoded by specified gene targets. OncoGenex Technologies is solely responsible for all product development activities for antisense compounds under this collaboration.
OGX-011: Under an agreement made in November 2001, the University of British Columbia (UBC) granted to OncoGenex Technologies an exclusive, worldwide license to commercialize its existing intellectual property and any improvements related to clusterin.
On September 30, 2010, Teva Pharmaceutical Industries Limited and OncoGenex Pharmaceuticals, Inc. announced the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. ONCOGENEX PHARMACEUTICALS, INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. ONCOGENEX PHARMACEUTICALS, INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. ONCOGENEX PHARMACEUTICALS, INC. SWOT ANALYSIS
4. ONCOGENEX PHARMACEUTICALS, INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. ONCOGENEX PHARMACEUTICALS, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. OncoGenex Pharmaceuticals, Inc. Direct Competitors
5.2. Comparison of OncoGenex Pharmaceuticals, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of OncoGenex Pharmaceuticals, Inc. and Direct Competitors Stock Charts
5.4. OncoGenex Pharmaceuticals, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. OncoGenex Pharmaceuticals, Inc. Industry Position Analysis
6. ONCOGENEX PHARMACEUTICALS, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. ONCOGENEX PHARMACEUTICALS, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. ONCOGENEX PHARMACEUTICALS, INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. ONCOGENEX PHARMACEUTICALS, INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. ONCOGENEX PHARMACEUTICALS, INC. PORTER FIVE FORCES ANALYSIS2
12. ONCOGENEX PHARMACEUTICALS, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
OncoGenex Pharmaceuticals, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
OncoGenex Pharmaceuticals, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
OncoGenex Pharmaceuticals, Inc. Major Shareholders
OncoGenex Pharmaceuticals, Inc. History
OncoGenex Pharmaceuticals, Inc. Products
Revenues by Segment
Revenues by Region
OncoGenex Pharmaceuticals, Inc. Offices and Representations
OncoGenex Pharmaceuticals, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
OncoGenex Pharmaceuticals, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
OncoGenex Pharmaceuticals, Inc. Capital Market Snapshot
OncoGenex Pharmaceuticals, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
OncoGenex Pharmaceuticals, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
OncoGenex Pharmaceuticals, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
OncoGenex Pharmaceuticals, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
OncoGenex Pharmaceuticals, Inc. 1-year Stock Charts
OncoGenex Pharmaceuticals, Inc. 5-year Stock Charts
OncoGenex Pharmaceuticals, Inc. vs. Main Indexes 1-year Stock Chart
OncoGenex Pharmaceuticals, Inc. vs. Direct Competitors 1-year Stock Charts
OncoGenex Pharmaceuticals, Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?